WHO ICTRP trial
A study of Adavosertib as Treatment for Uterine Serous Carcinoma
EUCTR2020-000138-16-FR · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2020-000138-16-FR |
|---|---|
| Public title | A study of Adavosertib as Treatment for Uterine Serous Carcinoma |
| Scientific title | A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma (ADAGIO) - ADAGIO |
| Primary sponsor | AstraZeneca AB |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | France;Spain;Germany;Italy |
| Conditions | Recurrent or persistent Uterine Serous Carcinoma (USC) in patients who have previously received at least 1 prior platinum-based chemotherapy regimen for the treatment of USC MedDRA version: 20.0 Level: SOC Classification code 10029104 Term… |
| Interventions | Product Name: Adavosertib capsule Product Code: AZD1775 Pharmaceutical Form: Capsule INN or Proposed INN: Adavosertib CAS Number: 1277170-60-1 Current Sponsor code: AZD1775 Other descriptive name: AZD1775 hemihydrate; L001739996-008U… |
| Registration date | Aug 20, 2020 |
| Target size | 120 |
| Secondary IDs | D601HC00002 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: